Athenix
"While the founders of Athenix have brought several products to market as part of larger organizations Athenix is our first experience building a venture backed company. We needed more than capital. Millennia has been particularly helpful to Athenix by making available specific firm expertise and insight in commercialization strategy. BMP has been instrumental in all phases of our growth from start-up to the recent negotiation of our first multi-year, multi million dollar product development partnership. Millennia brings valuable judgment and insight in business development, finance, fundraising, and strategy. We are very pleased to have such an active and committed investor."

Mike Koziel , CEO, President & Founder ,
Athenix

GlycoFi
"Pat Fortune is really a good Director. He is always responsive and never misses a call or meeting – asks good questions. He is a pleasure to work with, and well respected by the other Directors."

Charles E. Hutchinson, Ph.D., Co-Founder, Chief Executive Officer, Director,
GlycoFi, Inc.

ILEX Oncology
"Millennia’s professionals added tangible value to ILEX from day one because they could draw upon their extensive experience in the outsourced pharmaceutical services industry. As an active Board member, Millennia helped us expand our management team, refine our strategy, and reorganize our business to provide better service for our pharmaceutical clients."

Richard Love, President & Chief Executive Officer,
ILEX Oncology, Inc.

PAREXEL International
"The Millennia team acted as a true business partner as we grew our company. They helped refine our business strategy and worked closely with us as we became a leader in the contract research and medical marketing industry. We are now the third largest Contract Research Organization in the world, with approximately 5,000 employees in 35 countries. Together, we have built a sustainable international organization. Even today, seventeen years after their initial investment, the Millennia team continues to support us as we execute our growth strategy."

Josef von Rickenbach, President & Chief Executive Officer,
PAREXEL International Corporation